PresentationOperator Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related Macular Degeneration. Please note that this call is being recorded. [Operator Instructions] I would now like to turn the call to Tiffany Hamilton, Ocugen's Head of Corporate Communications. Please go ahead. ...

OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).The trial involved 51 patients aged 50 and older, randomized to receive either a medium or high dose of OCU410 or no treatment.Efficacy Signals Remain, But Below Interim TrendsThe optimal (mid-dose) cohort showed a 31% reduction in lesion growth versus control (p<0.05).Treatment slowed ellipsoid zone (EZ) loss by 27%, suggesting preservation of photoreceptor structure linked to visu ...

Ocugen (NasdaqCM:OCGN) Update / briefing March 24, 2026 08:00 AM ET Company ParticipantsAngela Qian - VP of Global Capital MarketsArun Upadhyay - Chief Scientific OfficerElemer Piros - Managing Director of Healthcare Equity ResearchHuma Qamar - Chief Medical OfficerJay Chhablani - ProfessorLejla Vajzovic - Professor of Ophthalmology and CME Program DirectorShankar Musunuri - Chairman, CEO, and Co-founderSyed Shah - Vice Chair for Research and Digital MedicineTiffany Hamilton - Head of Corporate Communicatio ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectivelyNo serious adverse events and no adverse events of special interest related to OCU410 reported to date MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnol ...

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, M ...

Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was initiated with an Outperform rating and a $10 price target at Oppenheimer. The firm noted that they find the company to be an upcoming leader in gene therapy for blinding ocular disorders. Oppenheimer highlighted the company’s lead asset OCU400, which is currently in Phase 3 trials for retinitis pigmentosa. ​Retinitis pigmentosa is a disease affecting vision. OCU400 targets retinitis pig ...

Key Takeaways Ocugen's stock outlook hinges on late-stage data and filings across three retinal programs.OCGN reported $67.8M net loss in 2025, with rising R&D and pre-commercial costsCash runway into late 2026 raises dilution risk ahead of potential approvals in 2027Ocugen (OCGN) is entering a period where the stock can be driven more by calendar-based catalysts than traditional fundamentals. Multiple late-stage readouts and filing steps are lined up across its three lead retinal programs through 2026 and ...

Key Takeaways Ocugen targets multiple 2026-2027 catalysts across OCU400, OCU410ST and OCU410 programs.OCU400 phase III data due Q1 2027, with rolling BLA filing planned in Q3 2026.OCU410 and OCU410ST data readouts and filings could reshape expectations amid high execution risk.Ocugen (OCGN) is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The setup makes the next several quarters especially event ...

Key Takeaways Ocugen is advancing gene-agnostic therapies targeting multiple retinal mutations with one-time treatmentsOCGN plans a 2026 BLA filing for OCU400, with phase III data expected in early 2027.Pipeline programs like OCU410ST and OCU410 target large unmet needs with broad mutation coverage.Ocugen (OCGN) is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying mutations. T ...

In this article, we will look at the 10 High-Flying Penny Stocks to Buy.​On March 17, Jim Stoeffel and Andrew Palen, Portfolio Managers at Royce Investment Partners, released a research report discussing how micro-caps can stay on top. The report noted that micro-caps have been on an impressive bull run since the April lows in 2025, continuing through February 2026. Notably, the Russell Microcap index has surged 74.5% from April 8, 2025, to February 28, 2026, compared to the 39.7% gains of the Russell 1000 ...